DocOnline

doconline.com

DocOnline's vision is to make healthcare available everywhere for everyone at anytime and anywhere. How? Through a combination of steadily increasing Internet presence as well as computer intelligence, we can create a healthcare plan available to all people on their terms.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

CELL AND GENE THERAPY

EIGER BIOPHARMACEUTICALS PROVIDES UPDATE ON PLANS FOR EMERGENCY USE AUTHORIZATION APPLICATION FOLLOWING FDA FEEDBACK

Eiger BioPharmaceuticals, Inc. | October 06, 2022

news image

Eiger BioPharmaceuticals, Inc. a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus and other serious diseases, today announced that, following feedback from the U.S. Food and Drug Administration the company will not submit an emergency use authorization application of peginterferon lambda for the treatment of patients with mild-to-moderate COVID-19. Following Eiger's press release on September 6, 2022, the c...

Read More

AKERS BIOSCIENCES AND PREMAS BIOTECH ANNOUNCE PROGRESS IN ITS VACCINE DEVELOPMENT FOR COVID-19

PipelineReview | April 06, 2020

news image

Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced that its collaboration with Premas Biotech has successfully completed the milestone of obtaining clones of all three coronavirus antigens, Spike (S), Envelope (E), and Membrane (M) that they have selected for their vaccine candidate. The clone development process has four primary steps including first, the design and synthesis of the genes; second, the selecti...

Read More

DIAGNOSTICS

BIODESIX ANNOUNCES RESEARCH AGREEMENT WITH TOP US CANCER CENTER

Biodesix | June 06, 2022

news image

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that it intends to develop a new novel minimal residual disease (MRD) test as a part of a master sponsored research agreement (MSRA) with Memorial Sloan Kettering Cancer Center (MSK). In addition, the MSRA between MSK and Biodesix also includes the potential future development of other diagnostic tests aimed at improving the treatment of cancer. Read More

INDUSTRIAL IMPACT

NAVROGEN INC. AND TAVOTEK BIOTHERAPEUTICS ANNOUNCE STRATEGIC COLLABORATION TO IMPROVE THERAPEUTIC EFFICACY OF ANTIBODY PIPELINE AGENTS

Navrogen Inc. | August 18, 2021

news image

Navrogen Inc. a biopharmaceutical company specialized in developing therapies for cancer and immune-related disorders, and Tavotek Biotherapeutics, a biotech company focusing on novel multi-specific antibodies in immuno-oncology and autoimmune diseases, announced today that they have entered into a strategic collaboration to identify and develop experimental monoclonal antibodies (mAbs) for the treatment of various cancer indications. Under the agreement, Navrogen and Tavotek will...

Read More
news image

CELL AND GENE THERAPY

EIGER BIOPHARMACEUTICALS PROVIDES UPDATE ON PLANS FOR EMERGENCY USE AUTHORIZATION APPLICATION FOLLOWING FDA FEEDBACK

Eiger BioPharmaceuticals, Inc. | October 06, 2022

Eiger BioPharmaceuticals, Inc. a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus and other serious diseases, today announced that, following feedback from the U.S. Food and Drug Administration the company will not submit an emergency use authorization application of peginterferon lambda for the treatment of patients with mild-to-moderate COVID-19. Following Eiger's press release on September 6, 2022, the c...

Read More
news image

AKERS BIOSCIENCES AND PREMAS BIOTECH ANNOUNCE PROGRESS IN ITS VACCINE DEVELOPMENT FOR COVID-19

PipelineReview | April 06, 2020

Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced that its collaboration with Premas Biotech has successfully completed the milestone of obtaining clones of all three coronavirus antigens, Spike (S), Envelope (E), and Membrane (M) that they have selected for their vaccine candidate. The clone development process has four primary steps including first, the design and synthesis of the genes; second, the selecti...

Read More
news image

DIAGNOSTICS

BIODESIX ANNOUNCES RESEARCH AGREEMENT WITH TOP US CANCER CENTER

Biodesix | June 06, 2022

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that it intends to develop a new novel minimal residual disease (MRD) test as a part of a master sponsored research agreement (MSRA) with Memorial Sloan Kettering Cancer Center (MSK). In addition, the MSRA between MSK and Biodesix also includes the potential future development of other diagnostic tests aimed at improving the treatment of cancer. Read More

news image

INDUSTRIAL IMPACT

NAVROGEN INC. AND TAVOTEK BIOTHERAPEUTICS ANNOUNCE STRATEGIC COLLABORATION TO IMPROVE THERAPEUTIC EFFICACY OF ANTIBODY PIPELINE AGENTS

Navrogen Inc. | August 18, 2021

Navrogen Inc. a biopharmaceutical company specialized in developing therapies for cancer and immune-related disorders, and Tavotek Biotherapeutics, a biotech company focusing on novel multi-specific antibodies in immuno-oncology and autoimmune diseases, announced today that they have entered into a strategic collaboration to identify and develop experimental monoclonal antibodies (mAbs) for the treatment of various cancer indications. Under the agreement, Navrogen and Tavotek will...

Read More